Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VTP-1000 in Adults With Celiac Disease
NCT06310291Phase 1Active, not recruiting
- Sponsor
- Barinthus Biotherapeutics
- Start
- Aug 2024
- Primary completion
- Nov 2026
- Modality
- Prophylactic Vaccines, Nanoparticles, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VTP-1000 in celiac disease (8 arms), sponsored by Barinthus Biotherapeutics. Primary endpoints: Treatment Emergent Adverse Events, Serious Adverse Events and Adverse Events of Special Interest at 57 days, Changes from baseline in standard Clinical Chemistry laboratory safety parameters at 57 days and 7 more. Started Aug 2024; status: active, not recruiting.
02
Drugs
VTP-1000
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT06310291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06310291.